Exact Sciences Corporation Stock Drops 4.20%

Trending News 🌥️

Exact Sciences($NASDAQ:EXAS) Corporation’s stock dropped 4.20% from its latest closing price, compared to the recent 1-year high of $107.00. This aggressive move by the company has investors wondering how to trade the stock now. Some believe that this drop is a buying opportunity, while others think that the company is in for a long-term decline. No matter what your opinion is, it’s important to do your own research before investing in any company.

Market Price

This is largely due to the negative media exposure the company has been receiving lately. On Friday, EXACT SCIENCES stock opened at $34.0 and closed at $33.4, down by 2.7% from its last closing price of 34.4. The company’s stock has been on a steady decline since last week and there is no indication that this trend will reverse anytime soon.

VI Analysis

Company’s fundamentals reflect its long term potential, below analysis on EXACT SCIENCES are made simple by VI app. Based on VI Risk Rating, EXACT SCIENCES is a high risk investment in terms of financial and business aspects. You may look at what are the business and financial areas presenting potential risks in our website. The company’s fundamentals reflect its long term potential.

However, the company is facing some risks that could impact its ability to meet its financial and business goals. The VI app can help you identify these risks so that you can make an informed decision about whether or not to invest in the company.

Summary

The Exact Sciences Corporation is a biotechnology company that specializes in the early detection of cancer. The company’s stock dropped 4.20% on Wednesday after a series of negative media reports. Investors may be worried about the company’s ability to continue to grow in the face of increasing competition. Exact Sciences is currently the only company that offers a non-invasive colon cancer screening test, but several other companies are working on similar tests.

There are also concerns that the company’s products may not be covered by insurance companies in the future. Insurance coverage is a key factor in whether or not people will be able to afford the tests. Despite the negative news, Exact Sciences continues to be a strong company.